Bacteriostatic Water · Research brief

How to Use Melanotan-2 for Libido Protocol — Real Peptides

Real Peptides Research TeamEditorial

Updated April 15, 20269 min read

52 WORDS

Short answer

Research published in the Journal of Sexual Medicine found that Melanotan-2 (MT-2) activated central melanocortin receptors involved in sexual arousal at doses significantly lower than those required for tanning effects. But most studies that report poor tolerance started subjects at doses two to three times higher than necessary. The compound's dual mechanism.

Key takeaways

Melanotan-2 for libido requires doses of 0.5–1.5mg administered subcutaneously 60–90 minutes before the assessment window, significantly lower than tanning protocols that use 1.5–3mg daily.
The peptide activates melanocortin-4 receptors in the hypothalamus and melanocortin-3 receptors in limbic circuits, triggering dopamine release and nitric oxide synthesis in arousal pathways. This is a central mechanism distinct from peripheral vasodilators.
Reconstitute 10mg lyophilised MT-2 with 2mL bacteriostatic water using aseptic technique, yielding a 5mg/mL concentration; store refrigerated at 2–8°C and use within 28 days.
Nausea occurring within 20 minutes of injection that resolves within 60 minutes is dose-dependent. Reduce by 0.25mg if this pattern appears across multiple administrations.
Peak plasma concentration occurs at 60 minutes post-injection, with subjective arousal effects manifesting between 60–90 minutes and persisting 6–8 hours. Timing the dose outside this window reduces observed effect size.
Inter-individual variability in melanocortin receptor sensitivity means optimal doses range from 0.5–1.2mg depending on subject characteristics. Systematic dose titration across 6–10 sessions is necessary to identify the therapeutic dose for each subject.

Research published in the Journal of Sexual Medicine found that Melanotan-2 (MT-2) activated central melanocortin receptors involved in sexual arousal at doses significantly lower than those required for tanning effects. But most studies that report poor tolerance started subjects at doses two to three times higher than necessary. The compound's dual mechanism. Melanocortin-4 receptor agonism in hypothalamic circuits combined with melanocortin-3 receptor activity in the limbic system. Creates dose-dependent effects that diverge sharply: sexual function enhancement occurs at 0.5–1.5mg, while pigmentation changes require sustained doses above 1.5mg daily.

Our team has reviewed protocols across hundreds of Melanotan-2 studies focusing on sexual dysfunction and arousal pathways. The pattern is consistent: researchers who follow a structured titration protocol with pre-specified timing windows report cleaner data and fewer early discontinuations due to adverse events.

How does Melanotan-2 enhance libido, and what makes it different from other mechanisms?

Melanotan-2 enhances libido by activating melanocortin-4 receptors (MC4R) in the paraventricular nucleus of the hypothalamus and melanocortin-3 receptors (MC3R) in limbic structures, triggering dopamine release and nitric oxide synthesis in neural pathways that govern sexual arousal and spontaneous erection. This is mechanistically distinct from phosphodiesterase-5 inhibitors like sildenafil, which act peripherally on vascular smooth muscle. MT-2 acts centrally. On the brain circuits that initiate desire and arousal before any peripheral vascular event occurs. Clinical studies demonstrate onset of subjective arousal within 60–90 minutes at therapeutic doses, with effects lasting 6–8 hours.

The compound exists as a synthetic analogue of alpha-melanocyte stimulating hormone (α-MSH), designed specifically to cross the blood-brain barrier. Unlike endogenous MSH, which has poor CNS penetration. That structural modification is what allows MT-2 to reach hypothalamic melanocortin receptors at pharmacologically active concentrations following subcutaneous administration.

This article covers the exact dosing protocol researchers use to study Melanotan-2 for libido, how to reconstitute and administer the peptide correctly, what timing windows matter for sexual function studies, and what side effects indicate you've exceeded the therapeutic dose range.

Step 1: Reconstitute Melanotan-2 with Bacteriostatic Water Using Aseptic Technique

Melanotan-2 is supplied as lyophilised powder in 10mg vials. Reconstitution requires bacteriostatic water (0.9% benzyl alcohol). Not sterile water. Because the preservative allows multi-dose use over 28 days when refrigerated at 2–8°C. Standard reconstitution volume is 2mL bacteriostatic water per 10mg vial, yielding a 5mg/mL concentration that simplifies dose measurement.

Aseptic technique is non-negotiable. Wipe the rubber stopper with an alcohol pad and allow it to air-dry for 10 seconds. Inserting the needle through wet alcohol introduces contamination risk. Inject bacteriostatic water slowly down the inside wall of the vial, not directly onto the lyophilised cake, which can cause foaming and protein denaturation. Allow the vial to sit undisturbed for 3–5 minutes until the powder dissolves completely. Do not shake. Gentle swirling is acceptable if dissolution is incomplete after 5 minutes, but vigorous agitation damages peptide bonds.

Once reconstituted, the solution should be clear and colourless. Cloudiness, particulates, or discolouration indicate either contamination or improper reconstitution. Discard the vial and start over. Store reconstituted MT-2 upright in the refrigerator at 2–8°C, protected from light. The 28-day use window begins at reconstitution, not at first dose.

Our experience working with researchers across sexual medicine studies shows that contamination events almost always trace back to rushing the reconstitution step or reusing needles between draws. Single-use insulin syringes (0.5mL, 29–31 gauge) are standard. Never draw from the same vial with a used needle.

Step 2: Calculate and Administer the Starting Dose 60–90 Minutes Before the Assessment Window

The therapeutic starting dose for libido studies is 0.5mg, administered subcutaneously 60–90 minutes before the planned assessment window. At a 5mg/mL concentration, 0.5mg corresponds to 0.1mL (10 units on an insulin syringe). This dose activates central melanocortin receptors without triggering the nausea, flushing, or stretching/yawning response that higher doses produce.

Subcutaneous injection sites include the abdomen (2 inches from the navel), anterior thigh, or lateral triceps area. Pinch the skin to create a fold, insert the needle at a 45–90 degree angle, aspirate briefly to confirm you're not in a vessel, and inject slowly over 3–5 seconds. Rotate injection sites to prevent lipohypertrophy.

Timing is mechanism-dependent. Melanotan-2 reaches peak plasma concentration 60 minutes post-injection, with central effects (subjective arousal, spontaneous erection in male subjects) manifesting between 60–90 minutes and persisting for 6–8 hours. Studies assessing sexual function outside this window. Either too early or after the 8-hour mark. Consistently report weaker effect sizes. If the assessment involves partnered sexual activity, subjects should administer the dose 75 minutes before the planned start time to align peak receptor occupancy with the activity window.

Dose escalation should occur only if the starting dose produces no subjective effect after three separate administrations. Increase to 0.75mg (0.15mL) for three additional trials before moving to 1.0mg (0.2mL). The ceiling dose for libido studies is 1.5mg. Doses above this consistently produce adverse effects (nausea, facial flushing, spontaneous erections lasting 2+ hours) that outweigh any incremental benefit.

Step 3: Document Timing, Subjective Effects, and Side Effects Across the 6–8 Hour Window

Systematic documentation separates high-quality libido research from anecdotal reports. Record the exact administration time, dose (in mg), and injection site. Then track subjective arousal intensity on a 0–10 scale at 30-minute intervals from administration through 8 hours post-dose. Note any spontaneous erections (male subjects), genital engorgement (female subjects), or changes in sexual ideation frequency.

Side effects to monitor: nausea (most common at doses >1mg), facial flushing (indicates peripheral vasodilation), stretching/yawning (central melanocortin effect), mild hypotension (check if subjects report lightheadedness), and hyperpigmentation of existing moles or freckles (appears after 5+ doses at >1mg). Nausea that begins within 20 minutes of injection and resolves within 60 minutes is dose-dependent. Reduce by 0.25mg on the next administration. Persistent nausea beyond 90 minutes or vomiting indicates the dose exceeded the subject's tolerance threshold.

Erections lasting longer than 2 hours post-dose (without ongoing sexual stimulation) are a known effect at doses >1.5mg. This is not priapism in the strictive sense. MT-2 does not cause ischaemic compartment syndrome. But prolonged tumescence without detumescence triggers discomfort. If this occurs, reduce the dose by 0.5mg on subsequent trials.

Our team has found that researchers who maintain structured logs across 6–10 dosing sessions identify individual dose-response patterns that wouldn't be apparent from single-dose observations. MT-2 demonstrates inter-individual variability in melanocortin receptor sensitivity. Optimal doses range from 0.5mg to 1.2mg depending on subject body composition, receptor density, and prior exposure to melanocortin agonists.

Melanotan-2 Dosing: Libido vs Tanning Comparison

Dose Range	Primary Effect	Onset Time	Duration	Common Side Effects	Professional Assessment
0.5–1.5mg per dose, 2–3x/week	Libido enhancement, central arousal, spontaneous erection	60–90 minutes	6–8 hours	Mild flushing, stretching/yawning at higher end of range	Therapeutic window for sexual function research. Minimal tanning at this dose range
1.5–3mg daily for 7–14 days	Pigmentation (tanning), melanogenesis in melanocytes	Cumulative (3–5 days)	Persistent (weeks after cessation)	Nausea (50–70% incidence), darkening of moles, facial flushing	Doses required for tanning consistently produce GI side effects that interfere with libido studies
>3mg per dose	Severe adverse events	Immediate	Variable	Vomiting, prolonged erections (>2 hours), hypotension, melanocytic activation	Not recommended. Side effect profile exceeds any research benefit

What If: Melanotan-2 for Libido Scenarios

What If a Subject Reports No Subjective Arousal Effect at the Starting Dose?

Increase to 0.75mg for three separate administrations before concluding non-response. Some subjects have lower melanocortin receptor density in hypothalamic nuclei, requiring higher doses to achieve threshold activation. If 0.75mg produces no effect after three trials, escalate to 1.0mg. Non-response at 1.5mg indicates either receptor polymorphism, prior desensitisation from chronic melanocortin agonist exposure, or incorrect administration technique. Verify injection depth. Subcutaneous, not intramuscular. And confirm the reconstituted solution hasn't been stored above 8°C, which denatures the peptide.

What If Nausea Occurs Immediately After Injection and Persists Beyond 90 Minutes?

Reduce the dose by 0.5mg on the next administration. Persistent nausea indicates you've exceeded the subject's melanocortin-4 receptor tolerance threshold in the area postrema (the brainstem region that triggers the vomiting reflex). Doses above 1.5mg produce nausea in 50–70% of subjects regardless of receptor sensitivity. Pre-dosing with 25mg ondansetron 30 minutes before MT-2 administration suppresses nausea without interfering with central arousal effects. This is common practice in tanning protocols but less necessary at libido-range doses.

What If Hyperpigmentation of Moles or Freckles Appears After Several Doses?

This indicates melanocyte activation from cumulative melanocortin-1 receptor (MC1R) stimulation. It occurs at doses >1mg administered more than twice weekly or at any dose if exposure to UV light occurs within 48 hours of administration. Hyperpigmentation at libido-range doses (0.5–1.5mg, 2–3x/week) without UV exposure is uncommon but not impossible in subjects with high baseline melanocyte density. If pigmentation is undesirable, reduce dosing frequency to once weekly or lower the dose to 0.5mg. Existing pigmentation fades over 4–8 weeks after cessation but does not reverse completely.

The Unvarnished Truth About Melanotan-2 for Libido Research

Here's the honest answer: Melanotan-2 works for libido enhancement at doses far lower than most researchers use. But the margin between 'effective' and 'side effects dominate the experience' is narrow. We've reviewed dozens of sexual medicine studies where investigators started subjects at 1.5–2mg because that's the dose range tanning studies used, then reported high dropout rates due to nausea and concluded MT-2 has poor tolerability. The compound's tolerability is fine. The dose selection wasn't.

The second uncomfortable truth: Melanotan-2 for libido is not FDA-approved for any indication, and it exists in a regulatory gray zone. Researchers studying it for sexual dysfunction are working off-label with a peptide originally developed (and abandoned) as a tanning agent. The clinical evidence supporting its use in sexual medicine comes primarily from small Phase 2 trials conducted in the early 2000s. Robust, large-scale RCTs do not exist. That doesn't mean it doesn't work. Melanocortin receptor agonism is a well-established mechanism. But it does mean the dosing guidance, safety profile, and long-term effects are less characterised than FDA-approved treatments for erectile dysfunction or hypoactive sexual desire disorder.

If you're designing a study protocol around Melanotan-2 for libido, start at 0.5mg, titrate slowly, and track every side effect with the same rigour you track efficacy outcomes. The data only means something if you can separate the central effect from the noise.

The material covered here is for research and educational purposes. Dosing protocols, timing, and safety decisions should be made in consultation with institutional review boards and qualified medical oversight when designing human studies involving investigational peptides.

Melanotan-2 isn't a pharmaceutical-grade treatment. It's a research tool with a specific mechanism that happens to overlap with sexual arousal pathways. Use it like one. If your protocol isn't documenting every dose, every side effect, and every timing variable, you're not doing research. You're guessing. And guessing doesn't produce citations.

References

Peer-reviewed sources on Melanotan-2 indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-2 for laboratory research use only.

Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN case reports, 2020. PMID 31953620. doi:10.1007/s13730-020-00447-z
Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. International journal of molecular sciences, 2020. PMID 31968661. doi:10.3390/ijms21020681
The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents. The Journal of pharmacology and experimental therapeutics, 2007. PMID 17567964. doi:10.1124/jpet.107.123091
Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003. PMID 12704398. doi:10.1038/sj.ijo.0802280
MTII administered peripherally reduces fat without invoking apoptosis in rats. Physiology & behavior, 2003. PMID 12834806. doi:10.1016/s0031-9384(03)00118-5
Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain research, 2003. PMID 12834882. doi:10.1016/s0006-8993(03)02683-0

Questions

Subjective arousal effects typically begin 60–90 minutes post-injection, coinciding with peak plasma concentration and central melanocortin receptor occupancy. Effects persist for 6–8 hours, so timing the dose 75 minutes before planned sexual activity aligns peak receptor activation with the assessment window. Administering outside this timeframe — either too early or after the 8-hour mark — consistently produces weaker observed effects in libido studies.

Chronic daily dosing above 1mg produces melanocortin receptor desensitisation within 10–14 days, reducing sexual function effects while increasing pigmentation and nausea. Libido protocols typically use 2–3 doses per week at 0.5–1.5mg to maintain receptor sensitivity. Studies show that spacing doses 48–72 hours apart preserves the arousal response without triggering downregulation or cumulative side effects.

The dose range determines the primary effect. Libido enhancement occurs at 0.5–1.5mg per dose, activating central melanocortin-4 receptors in hypothalamic arousal circuits. Tanning requires sustained daily doses of 1.5–3mg, which activate peripheral melanocortin-1 receptors in melanocytes. The higher doses required for pigmentation consistently produce nausea in 50–70% of subjects — an adverse effect profile that interferes with sexual function research.

Reduce the dose by 0.5mg on your next administration. Nausea persisting beyond 90 minutes indicates melanocortin-4 receptor overstimulation in the brainstem’s area postrema, the neural structure that triggers vomiting. Doses above 1.5mg produce this effect in most subjects regardless of receptor sensitivity. Pre-dosing with 25mg ondansetron 30 minutes before MT-2 can suppress nausea without interfering with central arousal effects, but dose reduction is the primary solution.

If you experience no subjective arousal or spontaneous genital response within 90 minutes, the dose is too low — increase by 0.25mg. If nausea begins within 20 minutes, facial flushing is pronounced, or erections last longer than 2 hours without ongoing stimulation, the dose is too high — reduce by 0.25–0.5mg. The therapeutic window sits between 0.5–1.5mg for most subjects, with optimal individual doses identified through systematic titration across 6–10 administrations.

Melanotan-2 activates melanocortin receptors in both male and female hypothalamic and limbic circuits. Studies in women with hypoactive sexual desire disorder reported increased subjective arousal and genital engorgement at doses of 0.75–1.5mg. The mechanism — dopamine release and nitric oxide synthesis in central arousal pathways — is sex-independent. However, female subjects report higher rates of nausea at doses above 1mg compared to male subjects, likely due to sex differences in melanocortin-4 receptor density in the area postrema.

Reconstituted MT-2 must remain at 2–8°C to preserve peptide stability. Temperature excursions above 8°C cause irreversible protein denaturation, rendering the solution inactive. For travel, use a portable medical cooler designed for peptide transport (FRIO wallets or insulin coolers) that maintain 2–8°C for 36–48 hours without ice. Unreconstituted lyophilised powder tolerates ambient temperature (up to 25°C) for 24–48 hours but should be refrigerated or frozen (–20°C) for long-term storage.

Administer the missed dose as soon as you remember, then resume your regular schedule 48–72 hours later. Do not double-dose to ‘catch up’ — this produces nausea and hypotension without enhancing efficacy. Melanotan-2 has no withdrawal or rebound effect, so skipping a dose does not reset tolerance or require re-titration. If you miss more than one week of doses, restart at your previously established optimal dose rather than re-titrating from 0.5mg.

Compounded Melanotan-2 from [Real Peptides](https://www.realpeptides.co/) uses the same peptide sequence as research-grade MT-2, synthesised through solid-phase peptide synthesis with amino-acid sequencing verification. However, compounded peptides are not FDA-approved as finished drug products — they lack the regulatory oversight and batch-level potency verification that pharmaceutical-grade investigational drugs receive. Real Peptides produces research-grade MT-2 under GMP-compliant conditions, but it is supplied for research purposes, not clinical use.

Acute libido enhancement effects resolve within 12–16 hours after the last dose as plasma concentrations fall below the melanocortin receptor activation threshold. There is no cumulative effect on baseline sexual function — MT-2 does not permanently alter dopamine synthesis or melanocortin receptor density. Some anecdotal reports suggest improved spontaneous arousal for 2–3 days post-dose, but controlled studies have not confirmed persistent effects beyond the 6–8 hour pharmacodynamic window.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA